FSD-22546-50605
2 vaccinations
1 coded response
16 check-ins
1 free-text entry
0 call cases
- Sex
- Male
- Age at first dose
- 0-4
- ZIP prefix
- 232 / VA
- Registered
- 2022-06-28
- Relationship
- Child or adolescent in my care
- Guardian
- VSH-33370-41237
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2022-06-24
Dose 1 — Pfizer-BioNTech
-
2022-06-28
Registered in v-safe
- 2022-06-28
- 2022-07-10
-
2022-07-15
Dose 2 — Pfizer-BioNTech
- 2022-07-15
-
2022-07-16
Health check-in — days 1–6 daily, dose 2, under 3Feeling: Good · Irritability/cryingUnder 3 check-in
- 2022-07-17
- 2022-07-18
- 2022-07-20
- 2022-07-21
- 2022-07-24
- 2022-07-29
- 2022-08-06
- 2022-08-12
- 2022-08-21
- 2022-08-26
-
2022-10-14
Survey response — 3 months, dose 2, under 3MedDRA: Body temperature increased, Nasopharyngitis, Rhinorrhoea, Sneezing — Feeling: Fair · Be unable to work or attend schoolFree text: Cold symptoms - runny nose, sneezing, elevated tempMedDRA releases: 2024-11 · check-in free text available
- 2023-01-13
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2022-06-24 | Pfizer-BioNTech | No |
| 2 | 2022-07-15 | Pfizer-BioNTech | No |
Free text
Release 12 (Under 3) — 3 months, dose 2, under 3
Symptoms: Cold symptoms - runny nose, sneezing, elevated temp
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Body temperature increased | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | Sneezing | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release